Overview

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

Status:
Recruiting

Trial end date:
2024-10-31

Target enrollment:

Participant gender:

Summary

This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Acalabrutinib
Chlorambucil
Rituximab